Fig. 1Recurrence-free survivals across the body mass index (BMI) quartiles. There were no significant differences in recurrence-free survivals of papillary thyroid carcinoma patients across the BMI quartiles. The numbers of patients who remained no evidence of disease at each time point were described at the bottom.
Table 1Baseline Characteristics of Study Subjects and Associations between Body Mass Index Quartiles and Clinicopathological Features of Papillary Thyroid Carcinoma
Characteristic |
Total (n=1,189) |
Quartile according to body mass index |
P valueb
|
Q1a (n=290) |
Q2a (n=293) |
Q3a (n=301) |
Q4a (n=305) |
Age, yr |
45.3±11.9 |
44.7±11.3 |
38.4±11.8 |
48.2±10.1 |
49.7±11.2 |
<0.001c,d
|
<45 |
549 (46.2) |
146 (50.3) |
205 (70.0) |
96 (31.9) |
102 (33.4) |
<0.001d
|
≥45 |
640 (53.8) |
144 (49.7) |
88 (30.0) |
205 (68.1) |
203 (66.6) |
|
Gender |
|
|
|
|
|
|
Male |
157 (13.2) |
39 (13.4) |
39 (13.3) |
38 (12.6) |
41 (13.4) |
0.939 |
Female |
1,032 (86.8) |
251 (86.6) |
254 (86.7) |
263 (87.4) |
264 (86.6) |
|
Maximal tumor diameter, cm |
2.1±1.2 |
2.0±1.1 |
2.2±1.2 |
2.0±1.0 |
2.1±1.2 |
0.209c
|
≤2 |
775 (65.2) |
199 (68.6) |
178 (60.8) |
201 (66.8) |
197 (64.6) |
0.633 |
>2 |
414 (34.8) |
91 (31.4) |
115 (39.2) |
100 (33.2) |
108 (35.4) |
|
Extrathyroidal invasion |
|
|
|
|
|
|
Absent |
400 (33.6) |
92 (31.7) |
112 (38.2) |
101 (33.6) |
95 (31.1) |
0.586 |
Present |
789 (66.4) |
198 (68.3) |
181 (61.8) |
200 (66.4) |
210 (68.9) |
|
Mutifocal |
466 (39.2) |
115 (39.7) |
85 (29.0) |
128 (42.5) |
138 (45.2) |
0.015d
|
Lymph node metastasis |
|
|
|
|
|
|
pN0/Nx |
427 (35.9) |
100 (34.5) |
92 (31.4) |
121 (40.2) |
114 (37.4) |
0.330e
|
pN1a |
581 (48.9) |
145 (50.0) |
148 (50.5) |
138 (45.8) |
150 (49.2) |
|
pN1b |
181 (15.2) |
45 (15.5) |
53 (18.1) |
42 (14.0) |
41 (13.4) |
|
Distant metastasis, present |
25 (2.1) |
6 (2.1) |
11 (3.8) |
5 (1.7) |
3 (1.0) |
0.145 |
Staging according to TNM |
|
|
|
|
|
|
I/II |
638 (53.7) |
165 (56.9) |
217 (74.1) |
129 (42.9) |
127 (41.6) |
<0.001d
|
III/IV |
551 (46.3) |
125 (43.1) |
76 (25.9) |
172 (57.1) |
178 (58.4) |
|
Table 2Associations between Body Mass Index Quartile and Clinicopathological Features for Females
Variable |
Total (n=1,032) |
Quartile according to body mass index |
P valueb
|
Q1a (n=251) |
Q2a (n=254) |
Q3a (n=263) |
Q4a (n=264) |
Age, yr |
45.3±11.9 |
44.3±11.2 |
37.6±11.3 |
48.3±10.0 |
50.7±10.7 |
<0.001c,d
|
<45 |
476 (46.1) |
129 (51.4) |
187 (73.6) |
79 (30.0) |
81 (30.7) |
<0.001d
|
≥45 |
556 (53.9) |
122 (48.6) |
67 (26.4) |
184 (70.0) |
183 (69.3) |
|
Maximal tumor diameter, cm |
2.0±1.1 |
2.0±1.0 |
2.1±1.1 |
1.9±1.0 |
2.0±1.1 |
0.441c
|
≤2 |
695 (67.3) |
172 (68.5) |
160 (63.0) |
185 (70.3) |
178 (67.4) |
0.751 |
>2 |
337 (32.7) |
79 (31.5) |
94 (37.0) |
78 (29.7) |
86 (32.6) |
|
Extrathyroidal invasion |
|
|
|
|
|
|
Absent |
345 (33.4) |
78 (31.1) |
93 (36.6) |
91 (34.6) |
83 (31.4) |
0.928 |
Present |
687 (66.6) |
173 (68.9) |
161 (63.4) |
172 (65.4) |
181 (68.6) |
|
Mutifocal |
411 (39.8) |
99 (39.4) |
75 (29.5) |
113 (43.0) |
124 (47.0) |
0.008d
|
Lymph node metastasis |
|
|
|
|
|
|
pN0/Nx |
393 (38.1) |
93 (37.1) |
83 (32.7) |
113 (43.0) |
104 (39.4) |
0.210e
|
pN1a |
502 (48.6) |
126 (50.2) |
128 (50.4) |
122 (46.4) |
126 (47.7) |
|
pN1b |
137 (13.3) |
32 (12.7) |
43 (16.9) |
28 (10.6) |
34 (12.9) |
|
Distant metastasis, present |
20 (1.9) |
5 (2.0) |
9 (3.5) |
4 (1.5) |
2 (0.8) |
0.131 |
Staging according to TNM |
|
|
|
|
|
|
I/II |
559 (54.2) |
146 (58.2) |
196 (77.2) |
111 (42.2) |
106 (40.2) |
<0.001d
|
III/IV |
473 (45.8) |
105 (41.8) |
58 (22.8) |
152 (57.8) |
158 (59.8) |
|
Table 3Associations between Body Mass Index Quartiles and Clinicopathological Features for Males
Variable |
Total (n=157) |
Quartile according to body mass index |
P valueb
|
Q1a (n=39) |
Q2a (n=39) |
Q3a (n=38) |
Q4a (n=41) |
Age, yr |
45.2±12.5 |
47.1±12.1 |
43.0±14.1 |
47.6±11.1 |
43.5±12.1 |
0.234c
|
<45 |
73 (46.5) |
17 (43.6) |
18 (46.2) |
17 (44.7) |
21 (51.2) |
0.538 |
≥45 |
84 (53.5) |
22 (56.4) |
21 (53.8) |
21 (55.3) |
20 (48.8) |
|
Maximal tumor diameter, cm |
2.5±1.5 |
2.1±1.6 |
2.7±1.8 |
2.6±1.1 |
2.8±1.6 |
0.200c
|
≤2 |
80 (51.0) |
27 (69.2) |
18 (46.2) |
16 (42.1) |
19 (46.3) |
0.043d
|
>2 |
77 (49.0) |
12 (30.8) |
21 (53.8) |
22 (57.9) |
22 (53.7) |
|
Extrathyroidal invasion |
|
|
|
|
|
|
Absent |
55 (35.0) |
14 (35.9) |
19 (48.7) |
10 (26.3) |
12 (29.3) |
0.214 |
Present |
102 (65.0) |
25 (64.1) |
20 (51.3) |
28 (73.7) |
29 (70.7) |
|
Mutifocal |
55 (35.0) |
116 (41.0) |
10 (25.6) |
15 (39.5) |
14 (34.1) |
0.838 |
Lymph node metastasis |
|
|
|
|
|
|
pN0/Nx |
34 (21.7) |
7 (17.9) |
9 (23.1) |
8 (21.1) |
10 (24.4) |
0.570e
|
pN1a |
79 (50.3) |
19 (48.7) |
20 (51.3) |
16 (42.1) |
24 (58.5) |
|
pN1b |
44 (28.0) |
13 (33.3) |
10 (25.6) |
14 (36.8) |
7 (17.1) |
|
Distant metastasis, present |
5 (3.2) |
1 (2.6) |
2 (5.1) |
1 (2.6) |
1 (2.4) |
0.815 |
Staging according to TNM |
|
|
|
|
|
|
I/II |
79 (50.3) |
19 (48.7) |
21 (53.8) |
18 (47.4) |
21 (51.2) |
0.973 |
III/IV |
78 (49.7) |
20 (51.3) |
18 (46.2) |
20 (52.6) |
20 (48.8) |
|